The recalled medications are 4.2% sodium bicarbonate injection, 5 milliequivalents per 10 milliliters; 1% lidocaine hydrochloride injection, 50 milligrams per 5 milliliters; and 2% lidocaine hydrochloride injection, 100 milligrams per 5 milliliters. Lidocaine is a local anesthetic that has been in a monthslong shortage, and sodium bicarbonate is approved as an electrolyte replenisher and systemic alkalizer.
In an Oct. 2 post, the FDA said serious adverse events are unlikely, and Hospira has not received reports of adverse reactions related to the recall.
The solutions were distributed to hospitals and wholesalers in October 2022 throughout the United States and Puerto Rico, according to the agency.
“Wholesalers, hospitals, institutions and doctors with an existing inventory of a lot which is being recalled should discontinue use, stop distribution and quarantine the product immediately,” the FDA said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
